Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia

Bin Zhang, Le Xuan Truong Nguyen, Ling Li, Dandan Zhao, Bijender Kumar, Herman Wu, Allen Lin, Francesca Pellicano, Lisa Hopcroft, Yu Lin Su, Mhairi Copland, Tessa L. Holyoake, Calvin J. Kuo, Ravi Bhatia, David S. Snyder, Haris Ali, Anthony S. Stein, Casey Brewer, Huafeng Wang, Tinisha McDonald & 12 others Piotr Swiderski, Estelle Troadec, Ching Cheng Chen, Adrienne Dorrance, Vinod Pullarkat, Yate Ching Yuan, Danilo Perrotti, Nadia Carlesso, Stephen J. Forman, Marcin Kortylewski, Ya Huei Kuo, Guido Marcucci

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Leukemia stem cells (LSCs) in individuals with chronic myelogenous leukemia (CML) (hereafter referred to as CML LSCs) are responsible for initiating and maintaining clonal hematopoiesis. These cells persist in the bone marrow (BM) despite effective inhibition of BCR-ABL kinase activity by tyrosine kinase inhibitors (TKIs). Here we show that although the microRNA (miRNA) miR-126 supported the quiescence, self-renewal and engraftment capacity of CML LSCs, miR-126 levels were lower in CML LSCs than in long-term hematopoietic stem cells (LT-HSCs) from healthy individuals. Downregulation of miR-126 levels in CML LSCs was due to phosphorylation of Sprouty-related EVH1-domain-containing 1 (SPRED1) by BCR-ABL, which led to inhibition of the RAN-exportin-5-RCC1 complex that mediates miRNA maturation. Endothelial cells (ECs) in the BM supply miR-126 to CML LSCs to support quiescence and leukemia growth, as shown using mouse models of CML in which Mir126a (encoding miR-126) was conditionally knocked out in ECs and/or LSCs. Inhibition of BCR-ABL by TKI treatment caused an undesired increase in endogenous miR-126 levels, which enhanced LSC quiescence and persistence. Mir126a knockout in LSCs and/or ECs, or treatment with a miR-126 inhibitor that targets miR-126 expression in both LSCs and ECs, enhanced the in vivo anti-leukemic effects of TKI treatment and strongly diminished LSC leukemia-initiating capacity, providing a new strategy for the elimination of LSCs in individuals with CML.

Original languageEnglish (US)
Pages (from-to)450-462
Number of pages13
JournalNature Medicine
Volume24
Issue number4
DOIs
StatePublished - May 1 2018
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Stem cells
Bone
Leukemia
Bone Marrow
Stem Cells
Endothelial cells
Endothelial Cells
Protein-Tyrosine Kinases
MicroRNAs
Cell Self Renewal
Karyopherins
Phosphorylation
Hematopoiesis
Hematopoietic Stem Cells
Phosphotransferases
Down-Regulation

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. / Zhang, Bin; Nguyen, Le Xuan Truong; Li, Ling; Zhao, Dandan; Kumar, Bijender; Wu, Herman; Lin, Allen; Pellicano, Francesca; Hopcroft, Lisa; Su, Yu Lin; Copland, Mhairi; Holyoake, Tessa L.; Kuo, Calvin J.; Bhatia, Ravi; Snyder, David S.; Ali, Haris; Stein, Anthony S.; Brewer, Casey; Wang, Huafeng; McDonald, Tinisha; Swiderski, Piotr; Troadec, Estelle; Chen, Ching Cheng; Dorrance, Adrienne; Pullarkat, Vinod; Yuan, Yate Ching; Perrotti, Danilo; Carlesso, Nadia; Forman, Stephen J.; Kortylewski, Marcin; Kuo, Ya Huei; Marcucci, Guido.

In: Nature Medicine, Vol. 24, No. 4, 01.05.2018, p. 450-462.

Research output: Contribution to journalArticle

Zhang, B, Nguyen, LXT, Li, L, Zhao, D, Kumar, B, Wu, H, Lin, A, Pellicano, F, Hopcroft, L, Su, YL, Copland, M, Holyoake, TL, Kuo, CJ, Bhatia, R, Snyder, DS, Ali, H, Stein, AS, Brewer, C, Wang, H, McDonald, T, Swiderski, P, Troadec, E, Chen, CC, Dorrance, A, Pullarkat, V, Yuan, YC, Perrotti, D, Carlesso, N, Forman, SJ, Kortylewski, M, Kuo, YH & Marcucci, G 2018, 'Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia', Nature Medicine, vol. 24, no. 4, pp. 450-462. https://doi.org/10.1038/nm.4499
Zhang, Bin ; Nguyen, Le Xuan Truong ; Li, Ling ; Zhao, Dandan ; Kumar, Bijender ; Wu, Herman ; Lin, Allen ; Pellicano, Francesca ; Hopcroft, Lisa ; Su, Yu Lin ; Copland, Mhairi ; Holyoake, Tessa L. ; Kuo, Calvin J. ; Bhatia, Ravi ; Snyder, David S. ; Ali, Haris ; Stein, Anthony S. ; Brewer, Casey ; Wang, Huafeng ; McDonald, Tinisha ; Swiderski, Piotr ; Troadec, Estelle ; Chen, Ching Cheng ; Dorrance, Adrienne ; Pullarkat, Vinod ; Yuan, Yate Ching ; Perrotti, Danilo ; Carlesso, Nadia ; Forman, Stephen J. ; Kortylewski, Marcin ; Kuo, Ya Huei ; Marcucci, Guido. / Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. In: Nature Medicine. 2018 ; Vol. 24, No. 4. pp. 450-462.
@article{681fa685700c41c98deb95b176567d62,
title = "Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia",
abstract = "Leukemia stem cells (LSCs) in individuals with chronic myelogenous leukemia (CML) (hereafter referred to as CML LSCs) are responsible for initiating and maintaining clonal hematopoiesis. These cells persist in the bone marrow (BM) despite effective inhibition of BCR-ABL kinase activity by tyrosine kinase inhibitors (TKIs). Here we show that although the microRNA (miRNA) miR-126 supported the quiescence, self-renewal and engraftment capacity of CML LSCs, miR-126 levels were lower in CML LSCs than in long-term hematopoietic stem cells (LT-HSCs) from healthy individuals. Downregulation of miR-126 levels in CML LSCs was due to phosphorylation of Sprouty-related EVH1-domain-containing 1 (SPRED1) by BCR-ABL, which led to inhibition of the RAN-exportin-5-RCC1 complex that mediates miRNA maturation. Endothelial cells (ECs) in the BM supply miR-126 to CML LSCs to support quiescence and leukemia growth, as shown using mouse models of CML in which Mir126a (encoding miR-126) was conditionally knocked out in ECs and/or LSCs. Inhibition of BCR-ABL by TKI treatment caused an undesired increase in endogenous miR-126 levels, which enhanced LSC quiescence and persistence. Mir126a knockout in LSCs and/or ECs, or treatment with a miR-126 inhibitor that targets miR-126 expression in both LSCs and ECs, enhanced the in vivo anti-leukemic effects of TKI treatment and strongly diminished LSC leukemia-initiating capacity, providing a new strategy for the elimination of LSCs in individuals with CML.",
author = "Bin Zhang and Nguyen, {Le Xuan Truong} and Ling Li and Dandan Zhao and Bijender Kumar and Herman Wu and Allen Lin and Francesca Pellicano and Lisa Hopcroft and Su, {Yu Lin} and Mhairi Copland and Holyoake, {Tessa L.} and Kuo, {Calvin J.} and Ravi Bhatia and Snyder, {David S.} and Haris Ali and Stein, {Anthony S.} and Casey Brewer and Huafeng Wang and Tinisha McDonald and Piotr Swiderski and Estelle Troadec and Chen, {Ching Cheng} and Adrienne Dorrance and Vinod Pullarkat and Yuan, {Yate Ching} and Danilo Perrotti and Nadia Carlesso and Forman, {Stephen J.} and Marcin Kortylewski and Kuo, {Ya Huei} and Guido Marcucci",
year = "2018",
month = "5",
day = "1",
doi = "10.1038/nm.4499",
language = "English (US)",
volume = "24",
pages = "450--462",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia

AU - Zhang, Bin

AU - Nguyen, Le Xuan Truong

AU - Li, Ling

AU - Zhao, Dandan

AU - Kumar, Bijender

AU - Wu, Herman

AU - Lin, Allen

AU - Pellicano, Francesca

AU - Hopcroft, Lisa

AU - Su, Yu Lin

AU - Copland, Mhairi

AU - Holyoake, Tessa L.

AU - Kuo, Calvin J.

AU - Bhatia, Ravi

AU - Snyder, David S.

AU - Ali, Haris

AU - Stein, Anthony S.

AU - Brewer, Casey

AU - Wang, Huafeng

AU - McDonald, Tinisha

AU - Swiderski, Piotr

AU - Troadec, Estelle

AU - Chen, Ching Cheng

AU - Dorrance, Adrienne

AU - Pullarkat, Vinod

AU - Yuan, Yate Ching

AU - Perrotti, Danilo

AU - Carlesso, Nadia

AU - Forman, Stephen J.

AU - Kortylewski, Marcin

AU - Kuo, Ya Huei

AU - Marcucci, Guido

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Leukemia stem cells (LSCs) in individuals with chronic myelogenous leukemia (CML) (hereafter referred to as CML LSCs) are responsible for initiating and maintaining clonal hematopoiesis. These cells persist in the bone marrow (BM) despite effective inhibition of BCR-ABL kinase activity by tyrosine kinase inhibitors (TKIs). Here we show that although the microRNA (miRNA) miR-126 supported the quiescence, self-renewal and engraftment capacity of CML LSCs, miR-126 levels were lower in CML LSCs than in long-term hematopoietic stem cells (LT-HSCs) from healthy individuals. Downregulation of miR-126 levels in CML LSCs was due to phosphorylation of Sprouty-related EVH1-domain-containing 1 (SPRED1) by BCR-ABL, which led to inhibition of the RAN-exportin-5-RCC1 complex that mediates miRNA maturation. Endothelial cells (ECs) in the BM supply miR-126 to CML LSCs to support quiescence and leukemia growth, as shown using mouse models of CML in which Mir126a (encoding miR-126) was conditionally knocked out in ECs and/or LSCs. Inhibition of BCR-ABL by TKI treatment caused an undesired increase in endogenous miR-126 levels, which enhanced LSC quiescence and persistence. Mir126a knockout in LSCs and/or ECs, or treatment with a miR-126 inhibitor that targets miR-126 expression in both LSCs and ECs, enhanced the in vivo anti-leukemic effects of TKI treatment and strongly diminished LSC leukemia-initiating capacity, providing a new strategy for the elimination of LSCs in individuals with CML.

AB - Leukemia stem cells (LSCs) in individuals with chronic myelogenous leukemia (CML) (hereafter referred to as CML LSCs) are responsible for initiating and maintaining clonal hematopoiesis. These cells persist in the bone marrow (BM) despite effective inhibition of BCR-ABL kinase activity by tyrosine kinase inhibitors (TKIs). Here we show that although the microRNA (miRNA) miR-126 supported the quiescence, self-renewal and engraftment capacity of CML LSCs, miR-126 levels were lower in CML LSCs than in long-term hematopoietic stem cells (LT-HSCs) from healthy individuals. Downregulation of miR-126 levels in CML LSCs was due to phosphorylation of Sprouty-related EVH1-domain-containing 1 (SPRED1) by BCR-ABL, which led to inhibition of the RAN-exportin-5-RCC1 complex that mediates miRNA maturation. Endothelial cells (ECs) in the BM supply miR-126 to CML LSCs to support quiescence and leukemia growth, as shown using mouse models of CML in which Mir126a (encoding miR-126) was conditionally knocked out in ECs and/or LSCs. Inhibition of BCR-ABL by TKI treatment caused an undesired increase in endogenous miR-126 levels, which enhanced LSC quiescence and persistence. Mir126a knockout in LSCs and/or ECs, or treatment with a miR-126 inhibitor that targets miR-126 expression in both LSCs and ECs, enhanced the in vivo anti-leukemic effects of TKI treatment and strongly diminished LSC leukemia-initiating capacity, providing a new strategy for the elimination of LSCs in individuals with CML.

UR - http://www.scopus.com/inward/record.url?scp=85045320017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045320017&partnerID=8YFLogxK

U2 - 10.1038/nm.4499

DO - 10.1038/nm.4499

M3 - Article

VL - 24

SP - 450

EP - 462

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 4

ER -